AstraZeneca Stops Ultomiris Study Over Lack of Efficacy

AstraZeneca is halting a phase 3 trial of its immunotherapy Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis because the drug has not been shown to be effective.

The immunotherapy is meant to work by preventing the immune system from attacking healthy cells. The decision to halt the 382-participant global study followed a review of interim data by the independent data monitoring committee.

But AstraZeneca says it remains confident in the drug’s potential for treating rare diseases. The company gained access to Ultomiris in its $39 billion purchase of Boston, Mass.-based Alexion Pharmaceuticals last month.